作者: Quitterie Fontanges , Ricardo De Mendonca , Isabelle Salmon , Marie Le Mercier , Nicky D’Haene
DOI: 10.3390/IJMS17122117
关键词:
摘要: Promising targeted therapy and personalized medicine are making molecular profiling of tumours a priority. For colorectal cancer (CRC) patients, international guidelines made RAS (KRAS NRAS) status prerequisite for the use anti-epidermal growth factor receptor agents (anti-EGFR). Daily, new data emerge on theranostic prognostic role biomarkers, which is strong incentive validated, sensitive broadly available screening test in order to implement improve multi-modal strategy clinical trials. Next generation sequencing (NGS) has begun supplant other technologies genomic profiling. Targeted NGS method that allows parallel thousands short DNA sequences single offering cost-effective approach detecting multiple genetic alterations with minimum amount DNA. In present review, we collected concerning application technology setting cancer.